Sobi's board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive program

| Source: Swedish Orphan Biovitrum AB
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 8 May 2014
resolved - for the purpose of ensuring that the company can fulfill its
commitments under the long-term incentive program resolved by the annual general
meeting - on a directed share issue of no more than 396,180 redeemable and
convertible class C shares.

The general meeting also resolved to authorise the board of directors to resolve
on the repurchase of all issued class C shares by an offer directed to all
holders of class C shares. Repurchase under this authorisation may be made on
one or several occasions until the annual general meeting in 2015 and at a price
to no less than 100 per cent and no more than 105 per cent of the quotient value
of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorisation for
the said purpose by repurchasing of all issued class C shares against payment of
100 per cent of the quotient value of the share, corresponding to approximately
SEK 0.55 per share. Repurchase of the class C shares may be effected during the
period 21 July - 15 September 2014.

The company currently holds 4 688 948 own common shares but no own class C
shares. Subsequently to the effected repurchase of class C shares above, the
number of own class C shares will amount to 396,180.

The class C shares will, following the repurchase, be converted to common shares
to ensure delivery under the incentive program.

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at

For more information please contact
Media relations                                      Investor relations
Oskar Bosson                                       Jörgen Winroth
Head of Communications                     Vice President, Head of Investor
T: +46 70 410 71 80                             T:
+1 347-224-0819, +1 212-579-0506        

The information was released for public distribution on 18 July 2014, 09:00.